Skip to content
DataLookout
Start free
Menu

ClinicalTrials.gov term: Leukemia, Lymphocytic, Chronic, B-Cell

Chronic Lymphocytic Leukemia (CLL) clinical trials

Get alerts when Chronic Lymphocytic Leukemia (CLL) trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-05

What changed in the last 30 days

37 trials changed in the last 30 days: 1 stopped, 19 with notable changes, 17 with minor changes only.

  1. Notable: MK-1045 · B-cell Cancer (MK-1045-006) Recruitment opened Merck Sharp & Dohme LLCPhase 2 NCT07709000
  2. Minor: Collecting Blood Samples From · and Without Cancer to Evaluate Tests for Early Cancer Detection Trial sites expanded: 747 → 751 locations Alliance for Clinical Trials in OncologyNot specified NCT05334069
  3. Minor: Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body · B-Cell Malignancies Trial arms changed: 4 → 1 AbbViePhase 1 NCT05753501
  4. Minor: QOLIBRI · Benefits of Individual Physical Activity Intervention on Health-related Quality of Life · Chronic Lymphocytic Leukemia Primary completion pushed from Sep 30, 2026 to Oct 30, 2026 Janssen Cilag S.A.S.Not specified NCT06299540
  5. Minor: CAN3001 · PCI-32765 (Ibrutinib) Trial sites reduced: 175 → 156 locations Janssen Research & Development, LLCPhase 3 NCT01804686
  6. Minor: NX-5948 · CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) Trial sites expanded: 40 → 43 locations Nurix Therapeutics, Inc.Phase 2 NCT07221500
  7. Minor: NX-5948 in Combination With Other Agents · B-cell Malignancies Trial sites expanded: 6 → 9 locations Nurix Therapeutics, Inc.Phase 1/2 NCT07520006
  8. Minor: Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL Trial sites expanded: 224 → 261 locations Alliance for Clinical Trials in OncologyPhase 3 NCT07321652
  9. Notable: Panzyga in Primary Infection Prophylaxis · Chronic Lymphocytic Leukemia ("PRO-SID" Study) Results posted: Nov 2, 2026 OctapharmaPhase 3 NCT04502030
  10. Minor: Intermittent Duvelisib Dosing · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Study completion pushed from Oct 26, 2026 to Oct 25, 2027 City of Hope Medical CenterPhase 2 NCT03961672
  11. Notable: Keynatinib Primary completion pushed from Oct 10, 2027 to Oct 10, 2032 Medolution Ltd.Phase 1 NCT04807881
  12. Notable: Ibrutinib and Pembrolizumab · Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) Primary completion pushed from Nov 2025 to Apr 2027 Joshua BrodyPhase 1/2 NCT03153202
  13. Notable: Copanlisib and Nivolumab · Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma Primary and study completion pushed from Nov 4, 2026 to Oct 7, 2027 City of Hope Medical CenterPhase 1 NCT03884998
  14. Notable: Nemtabrutinib and Lisocabtagene Maraleucel · Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Start date pushed from Oct 15, 2026 to Dec 1, 2026 Fred Hutchinson Cancer CenterPhase 2 NCT07194980
  15. Minor: Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL Study completion moved earlier from May 31, 2028 to Jul 24, 2027 Novartis PharmaceuticalsPhase 1/2 NCT03960840
  16. Notable: Soundtrack-E · AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies Primary and study completion pushed from Jun 11, 2029 to May 20, 2030 AstraZenecaPhase 1/2 NCT06564038
  17. Minor: Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS Trial completed Dana-Farber Cancer InstitutePhase 1/2 NCT03534323
  18. Minor: Cellular Immunotherapy Following Chemotherapy · Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia Start date pushed from Sep 24, 2014 to Oct 14, 2014 City of Hope Medical CenterPhase 1 NCT02153580
  19. Notable: Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant Primary and study completion dates pushed to Feb 14, 2030 City of Hope Medical CenterPhase 1 NCT07020533
  20. Notable: CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors · CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Primary completion moved earlier from Jan 1, 2028 to Jan 1, 2027 City of Hope Medical CenterPhase 2 NCT06059391
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New sponsor entrants, last 90 days sponsors with their first trial in this area

First postedTrialSponsorPhase
2026-10-20 NCT07882732 RPM Signals in Outpatient CAR T Therapy Current Health new
2026-08-19 NCT07774390 Ibrutinib Plus Venetoclax Long-Term Outcomes in CLL European Research Initiative on CLL new
2026-08-13 NCT07763054 Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia… Haikou Affiliated Hospital of Central South University Xiangya School of Medicine new

Active trials by phase

Early Phase 1
3
Phase 1
77
Phase 1/2
47
Phase 2
136
Phase 2/3
1
Phase 3
46
Phase 4
6
Not charted: 99 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).

Top sponsors by active trials in this area

City of Hope Medical Center (21) · AstraZeneca (17) · M.D. Anderson Cancer Center (16) · Dana-Farber Cancer Institute (12) · Mayo Clinic (12) · National Cancer Institute (NCI) (12) · AbbVie (11) · BeOne Medicines (10) · Acerta Pharma BV (9) · National Heart, Lung, and Blood Institute (NHLBI) (8)

Get alerts when Chronic Lymphocytic Leukemia (CLL) trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.
Start monitoring free